NASDAQ:HOOK

Hookipa Pharma Stock Insider Trading

Healthcare > Biotechnology

Buy HOOK

*Your capital is at risk

$1.15

+0 (+0%)

At Close: Jun 03, 2026

Hookipa Pharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -62.50. In total, the insiders bought 10.58M and sold 135.91K HOOK shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-62.50
● Buy	10.58M shares
● Sell	135.91K shares
94% Buy Activity Moderate Positive Correlation
Sell Signal High Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -62.5. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 90.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 17, 2024 Buy	Stock Option (Right to Buy) A-Award	Peters Malte Director	Director	49 000 Value: $34.8K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Orlinger Klaus Chief Scientific Officer	Officer	367 300 Value: $279.1K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Aldag Jorn Chief Executive Officer	CEO / President	971 400 Value: $738.3K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Winderlich Mark Chief Development Officer	Officer	250 000 Value: $190.0K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Winderlich Mark Chief Development Officer	Officer	50 000 Value: $38.0K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Kandera Reinhard Chief Financial Officer	C-Suite Officer	406 200 Value: $308.7K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Necina Roman Chief Operations Officer	Officer	367 300 Value: $279.1K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Necina Roman Chief Operations Officer	Officer	367 300 Value: $279.1K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Kandera Reinhard Chief Financial Officer	C-Suite Officer	406 200 Value: $308.7K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Winderlich Mark Chief Development Officer	Officer	50 000 Value: $38.0K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Winderlich Mark Chief Development Officer	Officer	250 000 Value: $190.0K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Aldag Jorn Chief Executive Officer	CEO / President	971 400 Value: $738.3K
Apr 15, 2024 Buy	Stock Option (Right to Buy) A-Award	Orlinger Klaus Chief Scientific Officer	Officer	367 300 Value: $279.1K
Apr 01, 2024 Buy	Common Stock J-Other	Winderlich Mark Insider	Other	0 Value: $0
Apr 01, 2024 Buy	Common Stock J-Other	Winderlich Mark Insider	Other	0 Value: $0
Dec 20, 2023 Buy	Common Stock	Gilead Sciences, Inc. 10 Percent Owner	10% Owner	0 Value: $0
Dec 20, 2023 Buy	Common Stock	Gilead Sciences, Inc. 10 Percent Owner	10% Owner	0 Value: $0
Aug 21, 2023 Buy	Common Stock P-Purchase	Kandera Reinhard Chief Financial Officer	C-Suite Officer	7 000 Value: $5K
Aug 21, 2023 Buy	Common Stock P-Purchase	Kandera Reinhard Chief Financial Officer	C-Suite Officer	7 000 Value: $5K
Aug 16, 2023 Buy	Common Stock P-Purchase	Kandera Reinhard Chief Financial Officer	C-Suite Officer	8 000 Value: $6K
Aug 16, 2023 Buy	Common Stock P-Purchase	Kandera Reinhard Chief Financial Officer	C-Suite Officer	8 000 Value: $6K
Jul 11, 2023 Buy	Common Stock P-Purchase	Aldag Jorn Chief Executive Officer	CEO / President	5 000 Value: $4K
Jul 11, 2023 Buy	Common Stock P-Purchase	Aldag Jorn Chief Executive Officer	CEO / President	5 000 Value: $4K
Jul 07, 2023 Buy	Common Stock P-Purchase	Aldag Jorn Chief Executive Officer	CEO / President	5 000 Value: $4K
Jul 07, 2023 Buy	Common Stock P-Purchase	Aldag Jorn Chief Executive Officer	CEO / President	5 000 Value: $4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT HOOKIPA PHARMA INC.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-2...

Read Full Profile Here